The purpose of the study is to compare the risk of dementia in participants diagnosed with rheumatoid arthritis (RA) exposed to anti-tumor necrosis factor (TNF) therapy versus those exposed to methotrexate.

Inclusion Criteria:

• At least one claim for methotrexate or anti-TNF therapy during the study period. First medication received is the index medication, and date of first receipt is the index date
• 365 days of continuous pre-index observation immediately prior to the index date
• Participants have at least two occurrences of a diagnosis of rheumatoid arthritis within 365 days before and including the index date
• No prior use of methotrexate or an anti- tumor necrosis factor (TNF) therapy at any time prior to the index date
• Cohort follow-up persists until end of continuous observation or filling the comparator drug

Study population consists of participants who are new user of Anti-TNF therapy diagnosed with dementia and alzheimer's disease.